Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
BioNexus Gene Lab Corp: Increased maximum number of directors from seven to nine (effective 2023-01-01).
- Change
- bylaw amendment
- Effective
- 2023-01-01
Exact text from the filing
On July 21, 2013, the Board of Directors of the Company approved and ratified the Amended and Restated Bylaws (“Amended Bylaws”) of the Company to increase the maximum number of directors from seven (7) to nine (9), effective as of January 1, 2023.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
BioNexus Gene Lab Corp entered into Underwriting Agreement with Network 1 Financial Securities, Inc. valued at total gross proceeds of $5.75 million (effective 2023-07-20).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Network 1 Financial Securities, Inc.
- Value
- total gross proceeds of $5.75 million
- Effective
- 2023-07-20
Exact text from the filing
On July 20, 2023, BioNexus Gene Lab Corp. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Network 1 Financial Securities, Inc., as underwriter (the "Underwriter") pursuant to which the Company agreed to issue and sell, in a firm commitment underwritten public offering by the Company (the “Offering”) of 1,250,000 shares of common stock, priced at a public offering price of $4.00 per share. In addition, pursuant to the Underwriting Agreement, the Underwriter was granted a 45-day option (the “Over-Allotment Option") to purchase up to an additional 187,500 shares of common stock at the public offering price of $4.00 per share. The Underwriter fully exercised the Over-Allotment Option on July 24, 2023. The securities were offered by the Company pursuant to the registration statement on Form S-1 (File No. 333-269753), which was originally filed with the U.S. Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as a
View on SEC.gov